2 weeks Ago By Defense World Staff
Shares of Alto Neuroscience, Inc. ( NYSE:ANRO – Get Free Report ) have received a consensus rating of “Buy” from the seven research firms that are presently covering the stock, MarketBeat Ratings reports. Seven equities research analysts have rated the stock with a buy rating.
The average 12-month target price among brokers that have updated their coverage on the stock in the last year is $33.80. A number of equities research analysts recently weighed in on ANRO shares.
Wedbush restated an “outperform” rating and issued a $29.00 price target on shares of Alto Neuroscience in a report on Tuesday, September 10th. Rodman & Renshaw initiated coverage on Alto Neuroscience in a report on Friday, June 21st.
They issued a “buy” rating and a $43.00 target price on the stock. Finally, William Blair reaffirmed an “outperform” rating on shares of Alto Neuroscience in a research note on Tuesday, September 10th.
Read Our Latest Research Report on Alto Neuroscience Insider Buying and Selling Hedge Funds Weigh In On Alto Neuroscience Several hedge funds and other institutional investors have recently made changes to their positions in ANRO. Rhumbline Advisers acquired a new position in Alto Neuroscience during the 2nd quarter worth approximately $113,000. Federated Hermes Inc.
lifted its position in shares of Alto Neuroscience by 33.3% during the second quarter. Federated Hermes Inc.
now owns 12,000 shares of the company’s stock worth $128,000 after purchasing an additional 3,000 shares in the last quarter. University of Texas Texas AM Investment Managment Co. acquired a new position in shares of Alto Neuroscience during the first quarter worth $340,000.
Bank of New York Mellon Corp purchased a new position in shares of Alto Neuroscience in the second quarter valued at $252,000. Finally, Bowie Capital Management LLC acquired a new stake in Alto Neuroscience during the 2nd quarter valued at $462,000. Alto Neuroscience Stock Up 0.
8 % Shares of Alto Neuroscience stock opened at $12.10 on Friday. Alto Neuroscience has a 52-week low of $7.
91 and a 52-week high of $24.00. The company’s 50-day simple moving average is $11.
94 and its 200-day simple moving average is $12.89. The company has a current ratio of 19.
85, a quick ratio of 19.85 and a debt-to-equity ratio of 0.04.
Alto Neuroscience ( NYSE:ANRO – Get Free Report ) last posted its quarterly earnings results on Tuesday, August 13th. The company reported ($0.60) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.
67) by $0.07. Analysts predict that Alto Neuroscience will post -2.
63 earnings per share for the current year. About Alto Neuroscience ( Get Free Report Alto Neuroscience, Inc operates as a clinical-stage biopharmaceutical company in the United States. Its product pipeline comprising ALTO-100, which is in phase 2b clinical trial for the treatment of patients with major depressive disorder (MDD); and which is in phase 2a clinical trial for the treatment of post-traumatic stress disorder.
Recommended Stories Five stocks we like better than Alto Neuroscience Stock Market Holidays 2022-2025 – Here’s When the NYSE and NASDAQ Will be Closed CarMax’s Impressive Rally: What Investors Should Watch Next When to Sell a Stock for Profit or Loss MarketBeat Week in Review – 9/23 – 9/27 How Investors Can Identify and Successfully Trade Gap-Down Stocks Wake Up to This Biotech Stock That Still Has Big Potential Upside Receive News & Ratings for Alto Neuroscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alto Neuroscience and related companies with MarketBeat.com's FREE daily email newsletter ..
